查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930086

全球多發性骨髓瘤市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Multiple Myeloma Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 110 Pages | 商品交期: 請詢問到貨日

價格

多發性骨髓瘤市場成長因素

預計2025年全球多發性骨髓瘤市場規模將達到292.4億美元，並從2026年的310億美元增長至2034年的441.9億美元，預測期內複合年增長率（CAGR）為6.10%。北美地區將在2025年佔58.28%的市場佔有率，這主要得益於該地區較高的疾病診斷率、先進療法的積極應用以及眾多大型腫瘤公司的參與。

多發性骨髓瘤（MM）是一種罕見但嚴重的血液癌症，其特徵是漿細胞不受控制地增殖。如果不及時治療，可能致命。對疾病症狀的認識不斷提高、早期診斷的普及以及標靶治療和免疫療法的快速發展，顯著改善了疾病管理，推動了全球市場成長。

市場概覽及主要亮點

  • 市場規模（2025年）：292.4億美元
  • 市場規模（2026年）：310億美元
  • 市場規模（2034年）：441.9億美元
  • 複合年增長率：6.10%
  • 主要地區：北美（市佔率：58.28%（2025年））
  • 主要藥物類別：免疫調節劑

市場趨勢

強大的在研藥物推動成長

推動多發性骨髓瘤市場發展的關鍵趨勢之一是強大的新型療法研發管線。製藥公司正大力投資研發，以滿足尚未滿足的醫療需求。多個前景可觀的在研藥物正處於不同的臨床開發階段。例如，再生元公司的 REGN5458 (BCMAXCD3) 已展現出積極的臨床結果，凸顯了雙特異性抗體和標靶療法日益重要的作用。預計這些進展將在預測期內顯著推動市場擴張。

市場驅動因素

多發性骨髓瘤發生率上升

包括多發性骨髓瘤在內的血液系統癌症發生率的上升是市場成長的主要驅動因素。儘管多發性骨髓瘤被歸類為罕見癌症，但它在全球癌症病例中仍佔有相當大的比例。根據癌症網絡（Cancer Network）的統計數據，2016 年全球報告的多發性骨髓瘤病例約為 13 萬例，且發生率持續上升。診斷能力的提高和公眾意識的增強正在提高檢出率，並推動對有效療法的需求。

新產品上市及監管核准不斷增加

持續的研發投入推動了新產品的頻繁上市和監管審批，從而拓展了治療選擇。例如，2020 年 3 月，美國食品藥物管理局 (FDA) 批准了 Sarcrysa（isatuximab-IRFC）作為復發或難治性多發性骨髓瘤患者的聯合療法。儘管治癒率仍然有限，但疾病控制和預後的改善鼓勵了更多患者接受治療，從而提升了市場收入。

市場限制因子

治療費用高

儘管治療方法不斷進步，但高昂的治療費用仍然是一個重大障礙，尤其是在發展中國家。環磷酰胺的年治療費用為 5,800 美元，而 Pomalyst 的年治療費用約為 192,000 美元，這限制了患者獲得先進療法的機會。保險覆蓋不足、認知度低以及支付機制不完善進一步限制了新興市場治療的普及。

市場區隔分析

依藥物類別

到2026年，免疫調節藥物將佔市場主導地位，市佔率將達到65.07%。瑞復美（Revlimid，新基/百時美施貴寶）等藥物在實現良好的治療效果方面發揮關鍵作用。其他主要細分市場包括蛋白酶體抑制劑、抗CD38單株抗體、烷化劑和XPO1抑制劑等新興藥物類別。

依分銷管道

由於靜脈輸液治療的高使用率以及對受控臨床環境的需求，到2026年，醫院藥房將佔最大的市場佔有率，達到58.67%。儘管實體藥局的成長速度有所放緩，但由於網路藥局的便利性和處方配藥的便利性，預計將保持穩定成長。

區域分析

  • 北美地區仍然是關鍵區域，這得益於其較高的診斷率、強勁的醫療保健支出以及先進療法的廣泛應用。
  • 歐洲受益於監管核准的增加和專利到期時間的延長。
  • 亞太地區展現出強勁的成長潛力，這得益於龐大的患者群體以及達雷妥尤單抗（Darzalex）等關鍵藥物在日本的獲準。
  • 拉丁美洲以及中東和非洲地區目前處於成長初期，但隨著醫療保健基礎設施的改善，預計將會進一步擴張。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 主要國家多發性骨髓瘤盛行率（2025 年）
  • 在開發產品分析
  • 主要行業趨勢
  • 主要地區的監管環境
  • 多發性骨髓瘤治療經濟負擔分析
  • 新產品上市
  • 多發性骨髓瘤新興療法概述

第五章 全球多發性骨髓瘤多發性骨髓瘤市場分析：洞察與預測 (2021-2034)

  • 關鍵分析/摘要
  • 市場分析、洞察與預測：依藥物類別劃分
    • 免疫調節劑
    • 蛋白酶體抑制劑
    • 抗CD38單株抗體
    • 烷化劑
    • 其他
  • 市場分析、洞察與預測：依銷售管道劃分
    • 醫院藥房
    • 零售藥局和藥局
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美多發性骨髓瘤多發性骨髓瘤市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲多發性骨髓瘤市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區多發性骨髓瘤市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲多發性骨髓瘤市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲多發性骨髓瘤市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）成員國
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 主要的產業趨勢
  • 世界市場佔有率分析(2017年)
  • 競爭形勢儀表板
  • 主要企業的比較分析
  • 企業簡介
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • Amgen Inc.
  • ONO PHARMACEUTICAL CO., LTD.
  • Janssen Pharmaceuticals, Inc.
  • Genentech, Inc.(F． Hoffmann-La Roche Ltd)
  • CELGENE CORPORATION(Bristol Myers Squibb Company)
  • AbbVie Inc.
  • Sanofi
  • 其他的著名的企業

第12章 策略性建議

Product Code: FBI102693

Growth Factors of multiple myeloma Market

The global multiple myeloma market was valued at USD 29.24 billion in 2025 and is projected to grow from USD 31.00 billion in 2026 to USD 44.19 billion by 2034, registering a CAGR of 6.10% during the forecast period. North America dominated the market with a 58.28% share in 2025, supported by higher disease diagnosis rates, strong adoption of advanced therapeutics, and the presence of leading oncology companies.

Multiple myeloma (MM) is a rare but severe form of blood cancer characterized by the uncontrolled proliferation of plasma cells. If left untreated, the disease can be fatal. Rising awareness of disease symptoms, earlier diagnosis, and rapid advancements in targeted and immunotherapy-based treatments have significantly improved disease management, driving market growth globally.

Market Snapshot & Key Highlights

  • 2025 Market Size: USD 29.24 billion
  • 2026 Market Size: USD 31.00 billion
  • 2034 Market Size: USD 44.19 billion
  • CAGR: 6.10%
  • Dominant Region: North America (58.28% share in 2025)
  • Leading Drug Class: Immunomodulators

Market Trends

Strong Pipeline Candidates Driving Growth

One of the major trends shaping the multiple myeloma market is the robust pipeline of novel therapeutics. Pharmaceutical companies are heavily investing in R&D to address unmet clinical needs. Several promising pipeline candidates are in various stages of clinical development. For instance, Regeneron's REGN5458 (BCMAXCD3) has shown positive clinical outcomes, highlighting the growing role of bispecific antibodies and targeted therapies. These advancements are expected to significantly contribute to market expansion during the forecast period.

Market Drivers

Increasing Prevalence of Multiple Myeloma

The rising prevalence of blood cancers, including multiple myeloma, is a key driver of market growth. Although MM is classified as a rare cancer, it accounts for a substantial number of cancer cases worldwide. According to Cancer Network statistics, approximately 130,000 cases of multiple myeloma were reported globally in 2016, and incidence rates continue to rise. Improved diagnostic capabilities and increased awareness have led to higher detection rates, thereby increasing demand for effective treatment options.

Rising Product Launches and Regulatory Approvals

Continuous R&D efforts have resulted in frequent product launches and regulatory approvals, enhancing treatment availability. For example, in March 2020, the U.S. FDA approved Sarclisa (isatuximab-irfc) in combination therapy for patients with relapsed or refractory multiple myeloma. Although cure rates remain limited, improved disease management and better prognosis are encouraging more patients to seek treatment, boosting market revenue.

Market Restraint

High Cost of Treatment

Despite therapeutic advancements, high treatment costs remain a significant barrier, especially in developing economies. Annual treatment costs can range from USD 5,800 for cyclophosphamide to nearly USD 192,000 for Pomalyst, limiting access to advanced therapies. Lack of reimbursement coverage, limited awareness, and inadequate payment mechanisms further restrict treatment adoption in emerging markets.

Segmentation Analysis

By Drug Class

The immunomodulators segment dominated the market, accounting for 65.07% share in 2026. Drugs such as Revlimid (Celgene/Bristol Myers Squibb) have played a crucial role in achieving positive treatment outcomes. Other important segments include proteasome inhibitors, anti-CD38 monoclonal antibodies, alkylating agents, and emerging drug classes such as XPO1 inhibitors.

By Distribution Channel

Hospital pharmacies held the largest market share at 58.67% in 2026, due to the high use of intravenously administered therapies and the need for controlled clinical settings. Retail pharmacies registered slower growth, while online pharmacies are expected to grow steadily due to convenience and easier prescription fulfillment.

Regional Analysis

  • North America remains the leading region due to high diagnosis rates, strong healthcare expenditure, and advanced therapeutics adoption.
  • Europe benefits from increasing regulatory approvals and longer patent expiry timelines.
  • Asia Pacific shows strong growth potential, supported by large patient populations and approvals of key drugs such as DARZALEX in Japan.
  • Latin America and Middle East & Africa are in early growth stages but are expected to expand with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive, led by major oncology players such as Takeda, Bristol Myers Squibb, Amgen, Janssen, Genentech, AbbVie, Sanofi, and Karyopharm. Companies are focusing on product diversification, pipeline expansion, and regulatory approvals to strengthen their market position.

Conclusion

The global multiple myeloma market, valued at USD 29.24 billion in 2025, grew to USD 31.00 billion in 2026 and is projected to reach USD 44.19 billion by 2034. Market growth is driven by rising disease prevalence, strong R&D pipelines, increasing product approvals, and improved treatment outcomes. While high treatment costs remain a challenge, continuous innovation and expanding access to advanced therapies are expected to support sustained market growth during the forecast period.

Segmentation By Drug Class

  • Immunomodulators
  • Proteasome Inhibitor
  • Anti-CD38 Monoclonal Antibody
  • Alkylating Agents
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Multiple Myeloma - by Key Countries - 2025
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments
  • 4.4. Regulatory Scenario, by Key Regions
  • 4.5. Analysis Of Economic Burden of Multiple Myeloma Treatment
  • 4.6. New Product Launches
  • 4.7. Overview of Emerging Treatments for Multiple Myeloma

5. Global Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Immunomodulators
    • 5.2.2. Proteasome Inhibitor
    • 5.2.3. Anti-CD38 Monoclonal Antibody
    • 5.2.4. Alkylating Agents
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies & Drug Stores
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Drug Class
    • 6.2.1. Immunomodulators
    • 6.2.2. Proteasome Inhibitor
    • 6.2.3. Anti-CD38 Monoclonal Antibody
    • 6.2.4. Alkylating Agents
    • 6.2.5. Others
  • 6.3. Market Analysis - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies & Drug Stores
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Drug Class
    • 7.2.1. Immunomodulators
    • 7.2.2. Proteasome Inhibitor
    • 7.2.3. Anti-CD38 Monoclonal Antibody
    • 7.2.4. Alkylating Agents
    • 7.2.5. Others
  • 7.3. Market Analysis - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies & Drug Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis - By Country/ sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Drug Class
    • 8.2.1. Immunomodulators
    • 8.2.2. Proteasome Inhibitor
    • 8.2.3. Anti-CD38 Monoclonal Antibody
    • 8.2.4. Alkylating Agents
    • 8.2.5. Others
  • 8.3. Market Analysis - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies & Drug Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis - By Country/ sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Drug Class
    • 9.2.1. Immunomodulators
    • 9.2.2. Proteasome Inhibitor
    • 9.2.3. Anti-CD38 Monoclonal Antibody
    • 9.2.4. Alkylating Agents
    • 9.2.5. Others
  • 9.3. Market Analysis - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies & Drug Stores
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis - By Country/ sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Drug Class
    • 10.2.1. Immunomodulators
    • 10.2.2. Proteasome Inhibitor
    • 10.2.3. Anti-CD38 Monoclonal Antibody
    • 10.2.4. Alkylating Agents
    • 10.2.5. Others
  • 10.3. Market Analysis - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies & Drug Stores
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis - By Country/ sub-region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2017)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Takeda Pharmaceutical Company Limited
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. Novartis AG
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Teva Pharmaceutical Industries Ltd.
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Bristol Myers Squibb Company
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. Amgen Inc.
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. ONO PHARMACEUTICAL CO., LTD.
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Janssen Pharmaceuticals, Inc.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. CELGENE CORPORATION (Bristol Myers Squibb Company)
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)
    • 11.5.10. AbbVie Inc.
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & services,
      • 11.5.10.3. SWOT analysis,
      • 11.5.10.4. Recent developments,
      • 11.5.10.5. strategies,
      • 11.5.10.6. financials (based on availability)
    • 11.5.11. Sanofi
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & services,
      • 11.5.11.3. SWOT analysis,
      • 11.5.11.4. Recent developments,
      • 11.5.11.5. strategies,
      • 11.5.11.6. financials (based on availability)
    • 11.5.12. Other Prominent Players
      • 11.5.12.1. Overview,
      • 11.5.12.2. Products & services,
      • 11.5.12.3. SWOT analysis,
      • 11.5.12.4. Recent developments,
      • 11.5.12.5. strategies,
      • 11.5.12.6. financials (based on availability)

12. Strategic Recommendation

List of Tables

  • Table 1: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 3: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Region, 2021-2034
  • Table 4: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 5: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 6: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country, 2021-2034
  • Table 7: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 8: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 9: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 11: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 14: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 17: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Multiple Myeloma Market Revenue Breakdown (US$ Bn, %) by Region, 2025 & 2034
  • Figure 2: Global Multiple Myeloma Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Multiple Myeloma Market Forecast (US$ Bn), by Immunomodulators, 2021-2034
  • Figure 4: Global Multiple Myeloma Market Forecast (US$ Bn), by Proteasome Inhibitor, 2021-2034
  • Figure 5: Global Multiple Myeloma Market Forecast (US$ Bn), by Anti-CD38 Monoclonal Antibody, 2021-2034
  • Figure 6: Global Multiple Myeloma Market Forecast (US$ Bn), by Alkylating Agents, 2021-2034
  • Figure 7: Global Multiple Myeloma Market Forecast (US$ Bn), by Others, 2021-2034
  • Figure 8: Global Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 9: Global Multiple Myeloma Market Forecast (US$ Bn), by Hospital Pharmacies, 2021-2034
  • Figure 10: Global Multiple Myeloma Market Forecast (US$ Bn), by Retail Pharmacies & Drug Stores, 2021-2034
  • Figure 11: Global Multiple Myeloma Market Forecast (US$ Bn), by Online Pharmacies, 2021-2034
  • Figure 12: Global Multiple Myeloma Market Value (US$ Bn), by Region, 2025 & 2034
  • Figure 13: North America Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 14: North America Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 15: North America Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 16: North America Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 17: North America Multiple Myeloma Market Value (US$ Bn), By Country, 2025 & 2034
  • Figure 18: North America Multiple Myeloma Market Value Share (%), By Country, 2025
  • Figure 19: Europe Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 20: Europe Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 21: Europe Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 22: Europe Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 23: Europe Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 24: Europe Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 25: Asia Pacific Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 26: Asia Pacific Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 27: Asia Pacific Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 28: Asia Pacific Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Asia Pacific Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Asia Pacific Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Latin America Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 32: Latin America Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 33: Latin America Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 34: Latin America Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Latin America Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Latin America Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 38: Middle East & Africa Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 39: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 40: Middle East & Africa Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 41: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 42: Middle East & Africa Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 43: Global Multiple Myeloma Market Share (%), By Company, 2025